Skip to main content

Table 5 Characteristics of patients with TEEs that were deemed possibly or probably related to study drug

From: Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study

Patient

TEE

Age

Sex

Race

BMI

Total dose

Max. infusion speed

No. of infusion episodes

Active infusion time

Time from start of last IVIg infusion to diagnosis of TEE (days)

Global disease activity

Risk factors for TEEs

Patient 2

DVT; severe

67 years

Male

White race

26.0 kg/m2

180 g; 1.978 g/kg

0.12 mL/kg/min

Two infusion episodes infused over 340 min

2

Moderate

• Hypertension

• Chronic heart failure

• Dyslipidaemia

• Ex-smoker

PE; severe

2

Patient 3

Cerebrovascular accident (TEE)

79 years

Female

White race

28.0 kg/m2

160 g; 2.025 g/kg

0.08 mL/kg/min

Four infusion episodes; infused over 555 min

29

Moderate

• Hypertension

• Palpitations

• Myocardial ischaemia

• Dyslipidaemia

Patient 4

PE; moderate

62 years

Male

White race

28.7 kg/m2

180 g; 1.978 g/kg

0.04 mL/kg/mina

Two infusion episodes

infused over 590 min

24

Moderate

• Hypertension

• Ventricular dilatation and left atrial dilatation

• Obesity

Patient 6

Cerebral infarction; moderate

70 years

Female

White race

22.5 kg/m2

110 g; 2.000 g/kg

0.12 mL/kg/min

Three infusion episodes

infused over 321 min

14

Mild

• Hypertension

Patient 7

Hypoaesthesia; mild

67 years

Female

White race

35.3 kg/m2

170 g; 2.000 g/kg

0.04 mL/kg/min

Two infusion episodes

infused over 592 min

10

Severe

• Supraventricular arrhythmia

• Hypercholesterolaemia

• Osteoporosis of the lumbar spine and fractures of the thoracic and lumbar spine

• Obesity

  1. BMI body mass index, DVT deep vein thrombosis, PE pulmonary embolism, TEE thromboembolic event
  2. aPatient 4 received IVIg at a maximum infusion rate of 0.12 mL/kg/min during the first period and at the reduced rate of 0.04 mL/kg/min during the extension period (from week 16, onwards). The PE occurred during the extension period, after the dose had been lowered